Consensus $738.28M. Backs FY25 adjusted EBITDA view $55M-$58M. The company said, “The Company revised its full-year 2025 guidance, as initially issued on January 15, 2025 to reflect the inclusion of $12 million to $14 million of revenue related to the acquisition of Pathline, LLC.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics reports Q1 EPS 0c, consensus (1c)
- NEO Upcoming Earnings Report: What to Expect?
- NeoGenomics price target lowered to $12 from $16 at BofA
- NeoGenomics Poised for Long-Term Growth: Buy Rating Affirmed Amid Strategic Leadership and Growth Strategy
- NeoGenomics completes acquisition of Pathline